Larimar Therapeutics, Inc. (LRMR)

О компании

Larimar Therapeutics Inc., formerly Zafgen, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for complex rare diseases using its cell penetrating peptide technology platform. The Company’s protein replacement therapy platform provides disease-modifying therapies that intends to deliver missing proteins inside the machinery of cells to treat devastating rare diseases that have no treatments available. The Company’s lead product candidate, CTI-1601, is a recombinant fusion protein intended to deliver human frataxin (FXN) into the mitochondria of patients with Friedreich’s ataxia (FA). CTI-1601 is in Phase I clinical program. The Company intends to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.